Retatrutide Injection Guide: How It's Administered

The Short Answer

Retatrutide is administered as a once-weekly subcutaneous injection using a pre-filled pen device. In clinical trials, injections are given in the abdomen, outer thigh, or back of the upper arm, following standard subcutaneous injection technique. The drug is not approved and is not available for prescription — the information below describes the administration protocols used in authorized clinical trials, not self-administration guidance.

This article describes how retatrutide is administered within authorized clinical trials. It is not a self-injection guide. Retatrutide is an investigational drug that is not available for prescription or purchase. Any use outside of authorized clinical trials is not sanctioned by regulatory agencies and carries significant safety risks.

Important Disclaimer

Retatrutide is an investigational drug that has not been approved by the FDA or any other regulatory authority. It is not available for prescription, sale, or dispensing anywhere in the world as of March 2026. The only legitimate way to receive retatrutide is through enrollment in an authorized clinical trial sponsored by Eli Lilly.

The information in this article describes the administration methods documented in clinical trial protocols and regulatory filings. It is presented for educational purposes — to help patients, healthcare providers, and researchers understand the practical aspects of retatrutide delivery. This article does not constitute self-administration guidance for any investigational or unapproved product.

Delivery Device

Pre-Filled Pen Design

Retatrutide is administered using a pre-filled single-dose pen device, similar to those used for tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy). Specific device details will be finalized as part of the regulatory approval process.

Device Handling

In clinical trial settings, participants receive training on pen device operation during their enrollment visit. Standard pen device handling includes:

• Inspecting the solution visually before each use (should be clear and colorless; do not use if cloudy, discolored, or contains particles)
• Priming the pen before first use (specific to manufacturer instructions)
• Attaching a new needle for each injection
• Disposing of used needles in a sharps container

Injection Sites Used in Clinical Trials

In TRIUMPH Phase 3 trials, the following injection sites are used:

Abdomen

• The preferred injection site for most subcutaneous peptide therapies
• Injection should be administered at least 2 inches (5 cm) from the navel
• Avoid the area directly around the navel, belt line, or any scars
• The abdomen provides consistent subcutaneous tissue depth and reliable absorption

Outer Thigh

• The anterior-lateral aspect of the thigh, approximately midway between the hip and knee
• Provides an accessible alternative when abdominal injection is not preferred
• Patients should avoid the inner thigh and areas near the knee joint

Back of the Upper Arm

• The posterior aspect of the upper arm, between the shoulder and elbow
• This site may require assistance from another person for proper injection technique
• Provides a third rotation option to minimize injection site reactions

Injection Technique

In clinical trials, trained healthcare professionals administer retatrutide following standard subcutaneous injection protocols. The injection is given using a pre-filled pen device at designated injection sites, following aseptic technique. Subcutaneous injection needles used with pen devices for incretin therapies are typically in the 27-31 gauge range, with lengths of 4-6 mm.

Site Rotation

Proper injection site rotation is essential for maintaining consistent drug absorption and minimizing injection site reactions:

• Rotate within and between anatomical regions: Alternate between abdomen, thigh, and arm across injection weeks
• Move at least 1 inch (2.5 cm) from the previous injection site within the same anatomical region
• Alternate sides: If injecting in the right abdomen one week, use the left abdomen or a different region the next week
• Avoid injecting into bruised, tender, hardened, or scarred areas: These can impair absorption and increase discomfort
• Keep a rotation log if helpful — some patients note the injection site and date to maintain consistent rotation

Poor site rotation can lead to lipohypertrophy (fatty lumps under the skin at overused injection sites), which can alter drug absorption kinetics and reduce treatment consistency.

Storage Requirements

Clinical trial protocols specify the following storage conditions:

Unopened Pens

• Clinical trial protocols specify storage at 2-8°C (36-46°F) for unopened product
• Stored in original packaging to protect from light
• Freezing is not permitted — frozen pens are discarded per trial protocol, as freezing can damage the peptide structure and alter potency

In-Use Pens

• Per trial protocols, in-use pens may be kept at room temperature (up to 30°C / 86°F) for a maximum of 21 days after first use
• Pens are not returned to refrigeration after room temperature storage has begun
• Unused portions are discarded after 21 days at room temperature per protocol

Dose Escalation Protocol

The Phase 3 TRIUMPH program uses a structured dose escalation protocol designed to optimize tolerability by gradually increasing the dose over several weeks.

Phase 3 Escalation Schedule

Key points about the escalation:

• Starting dose: All participants begin at 2 mg regardless of target dose
• Escalation intervals: 4 weeks at each dose level before increasing
• The 6 mg step was added in the Phase 3 protocol and was not present in the Phase 2 escalation. This intermediate step between 4 mg and 9 mg was introduced to improve gastrointestinal tolerability.
• Dose reduction is permitted: Participants who experience intolerable adverse events may reduce to the previous dose level. In clinical trials, this is managed by the investigator.
• Full escalation to 12 mg takes approximately 16 weeks from initiation

Why Escalation Matters

The dose escalation protocol exists because the gastrointestinal side effects of GLP-1 receptor agonists are dose-dependent and most severe during dose increases:

• Nausea occurred in 43.2% of TRIUMPH-4 participants at 12 mg
• Diarrhea occurred in 33.1% at 12 mg
• Vomiting occurred in 20.9% at 12 mg
• Skipping escalation steps or escalating too quickly increases the severity and duration of these adverse events
• The 6 mg intermediate step was specifically introduced to reduce the magnitude of GI side effects during the transition from 4 mg to 9 mg

Timing and Schedule

• Once weekly: Retatrutide is administered once per week, on the same day each week
• Time of day: No specific time-of-day requirement has been published. Patients in clinical trials are generally advised to choose a consistent time and maintain it
• Missed doses: Standard GLP-1 RA guidance suggests taking a missed dose as soon as remembered if within a defined window (typically within a few days), then resuming the regular schedule. Specific guidance for retatrutide has not been publicly detailed outside of trial protocols
• Food: No requirement to take with or without food

Frequently Asked Questions

What needle size is used for retatrutide injections?

Clinical trial pen devices use needles in the 27-31 gauge range, with 29-30 gauge being the most common. Needle length is typically 4-6 mm (short) for pen devices. These thin, short needles are designed for subcutaneous injection and produce minimal discomfort for most patients.

Where is the best place to inject retatrutide?

The abdomen (at least 2 inches from the navel) is the most commonly used injection site for subcutaneous GLP-1 receptor agonists due to consistent subcutaneous tissue depth and reliable absorption. The outer thigh and back of the upper arm are alternative sites. Rotation between sites is important.

How long does the injection take?

The injection itself takes only a few seconds. The pen device delivers the dose upon button press, and the needle should be held in place for at least 6 seconds after delivery to ensure the full dose is administered. Total preparation and injection time is typically under 5 minutes including skin cleaning and needle attachment.

What do clinical trial participants report about injection tolerability?

In clinical trials of subcutaneous incretin-based therapies using modern pen devices with 29-31 gauge needles, injection-site reactions are generally mild and infrequent. The TRIUMPH Phase 3 program reported low rates of injection-site adverse events. Injection-site pain, erythema, and pruritus are the most commonly reported local reactions across the GLP-1 receptor agonist class, and these are typically mild and transient.

How are missed doses handled in clinical trials?

Clinical trial protocols include specific guidance for missed doses, which is provided to participants by the study team. For approved GLP-1 receptor agonists with similar pharmacokinetics, the general protocol approach is to administer the missed dose as soon as possible if within a defined window (typically a few days of the scheduled date), then resume the regular weekly schedule. If the next scheduled dose is imminent, the missed dose may be skipped per investigator guidance. Specific missed-dose protocols for retatrutide have not been publicly detailed outside of trial documentation.

Summary

Retatrutide is administered as a once-weekly subcutaneous injection via a pre-filled pen device, similar to those used for other approved incretin therapies. In clinical trials, three injection sites are used: abdomen, outer thigh, and back of upper arm, with standard subcutaneous technique and site rotation. Clinical trial protocols specify refrigerated storage at 2-8°C for unopened product, or room temperature up to 30°C for a maximum of 21 days for in-use pens. The Phase 3 dose escalation protocol progresses from 2 mg to 4 mg to 6 mg to 9 mg to 12 mg at 4-week intervals. Retatrutide is investigational and not available outside of authorized clinical trials.